

Risankizumab Effective Against Refractory Psoriatic Arthritis

Risankizumab May Improve Symptoms of PsA

Risankizumab & Apremilast Come to Market in Canada

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

Study Results for 9 New Psoriatic Arthritis Drugs
